Meglithan

Metformin Hydrochloride and Linagliptin, the active ingredients in Meglithan, are a Biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They are prescribed to improve blood glucose control in adults with type 2 diabetes mellitus when diet, exercise, and monotherapy are insufficient, and they work together to reduce hepatic glucose output while enhancing insulin secretion in a glucose‑dependent manner.

GNH USA supplies Meglithan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Meglithan is indicated for the management of type 2 diabetes mellitus, targeting hyperglycemia through combined oral therapy. - Type 2 diabetes mellitus: improves glycemic control when added to diet, exercise and existing antidiabetic regimen. - Inadequate control on metformin alone: provides additional DPP‑4 inhibition to lower fasting and post‑prandial glucose. - Adults requiring combination therapy: reduces HbA1c levels as part of a comprehensive diabetes management plan.

Meglithan may cause adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: transient episodes of light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas.

When prescribing Meglithan, clinicians should observe several precautions to minimize risk. - Renal function assessment: evaluate creatinine clearance before initiation and periodically. - Hepatic impairment caution: use with care in patients with liver disease due to lactic acidosis risk. - Cardiovascular status: avoid in patients with unstable or acute heart failure. - Elderly patients: start at lower dose and monitor for hypoglycemia. - Concomitant medications: adjust dose when used with insulin or sulfonylureas to prevent low blood sugar. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Meglithan can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycemia. - Iodinated contrast agents: can impair renal function, increasing metformin accumulation. - Cimetidine: may increase linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - NSAIDs: may reduce renal perfusion, raising metformin levels.